A ground-breaking therapeutic company that is developing breakthrough peptide technology.
The company is focusing on delivering clinically transformative products that tackle the most challenging aspects of medicine today involving unique Patented Hybridtides® which provide critical enhancements.
Product:
Longevity Biotech Hybridtide®
Platform technology is based on a unique synthetic peptide scaffold that provides critical enhancements and is differentiated compared to other peptide scaffolds. The most important feature of this breakthrough technology is the prospect of oral delivery of Hybridtide-based peptide therapeutics. The company’s goal is to remove the frequent injections required for traditional biologic therapeutics and switch them into pill form.
